Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature 454, 894-898 (14 August 2008) | doi:10.1038/nature07199; Received 31 March 2008; Accepted 26 June 2008
Open Innovation Challenges
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
nature jobs
Group Leader Positions
- IMP
- Vienna Austria
System Engineer (Simulation and Modelling)
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection
Mary Premenko-Lanier1, Nelson B. Moseley1, Sarah T. Pruett2, Pablo A. Romagnoli1 & John D. Altman1
- Emory Vaccine Center and Department of Microbiology and Immunology; Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA
- Division of Psychobiology, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA
Correspondence to: Mary Premenko-Lanier1John D. Altman1 Correspondence and requests for materials should be addressed to J.D.A. (Email: jaltman@rmy.emory.edu) or M.P.-L. (Email: mflanie@emory.edu).
Abstract
For a wide variety of microbial pathogens, the outcome of the infection is indeterminate. In some individuals the microbe is cleared, but in others it establishes a chronic infection, and the factors that tip this balance are often unknown. In a widely used model of chronic viral infection, C57BL/6 mice clear the Armstrong strain of lymphocytic choriomeningitis virus (LCMV), but the clone 13 strain persists1, 2. Here we show that the Armstrong strain induces a profound lymphopenia at days 1–3 after infection, but the clone 13 strain does not. If we transiently augment lymphopenia by treating the clone-13-infected mice with the drug FTY720 at days 0–2 after infection, the mice successfully clear the infection by day 30. Clearance does not occur when CD4 T cells are absent at the time of treatment, indicating that the drug is not exerting direct antiviral effects. Notably, FTY720 treatment of an already established persistent infection also leads to viral clearance. In both models, FTY720 treatment preserves or augments LCMV-specific CD4 and CD8 T-cell responses, a result that is counter-intuitive because FTY720 is generally regarded as a new immunosuppressive agent3. Because FTY720 targets host pathways that are completely evolutionarily conserved, our results may be translatable into new immunotherapies for the treatment of chronic microbial infections in humans.
- Emory Vaccine Center and Department of Microbiology and Immunology; Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA
- Division of Psychobiology, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA
Correspondence to: Mary Premenko-Lanier1John D. Altman1 Correspondence and requests for materials should be addressed to J.D.A. (Email: jaltman@rmy.emory.edu) or M.P.-L. (Email: mflanie@emory.edu).
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Immunology Surprising side effectsNature News and Views (14 Aug 2008)
Taking the brake off T cells in chronic viral infectionNature Medicine News and Views (01 Mar 2006)
RESEARCH
Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract developmentKidney International Original Article
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cellsNature Letters to Editor (22 Apr 1993)
See all 64 matches for Research
